Omeros’ (OMER) Hold Rating Reaffirmed at Needham & Company LLC

Omeros (NASDAQ:OMER)‘s stock had its “hold” rating reiterated by stock analysts at Needham & Company LLC in a note issued to investors on Thursday,Benzinga reports.

Several other research firms have also recently commented on OMER. StockNews.com upgraded Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a report on Thursday, November 14th. Rodman & Renshaw assumed coverage on shares of Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target on the stock. Finally, Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Three equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $9.00.

Omeros Stock Up 37.3 %

Shares of Omeros stock opened at $10.24 on Thursday. Omeros has a fifty-two week low of $2.61 and a fifty-two week high of $13.60. The business’s fifty day moving average is $6.96 and its two-hundred day moving average is $5.13. The firm has a market cap of $593.41 million, a PE ratio of -4.43 and a beta of 1.97.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Cypress Capital Group grew its stake in Omeros by 40.0% during the second quarter. Cypress Capital Group now owns 35,000 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 10,000 shares during the period. Bank of New York Mellon Corp lifted its position in shares of Omeros by 16.6% during the second quarter. Bank of New York Mellon Corp now owns 218,580 shares of the biopharmaceutical company’s stock worth $887,000 after purchasing an additional 31,081 shares during the last quarter. Rhumbline Advisers grew its position in shares of Omeros by 6.1% during the 2nd quarter. Rhumbline Advisers now owns 111,778 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 6,435 shares during the last quarter. AQR Capital Management LLC bought a new position in Omeros during the 2nd quarter worth $105,000. Finally, SG Americas Securities LLC acquired a new stake in shares of Omeros in the third quarter valued at approximately $80,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.